This clinical trial is focused on studying a type of prostate cancer known as metastatic hormone-sensitive prostate cancer (mHSPC). The trial is investigating the effectiveness of a treatment called 177Lu-PSMA-617, which is used in combination with the standard care for this condition. The standard care may include various medications such as relugolix, goserelin acetate, triptorelin acetate, degarelix, bicalutamide, apalutamide, enzalutamide, darolutamide, abiraterone, flutamide, nilutamide, buserelin, histrelin, and leuprorelin. The purpose of the study is to evaluate how well the combination of 177Lu-PSMA-617 and standard care works compared to standard care alone in treating mHSPC.

Participants in the study will receive either the combination treatment or the standard care alone. The study will monitor the progress of the disease using imaging techniques to see if the cancer is spreading or staying the same. The trial will also look at overall survival, which means how long patients live after starting the treatment, and other health outcomes. The study will last for a period of time, and participants will be regularly checked to see how they are responding to the treatment.

This trial is important for understanding if adding 177Lu-PSMA-617 to the standard care can improve outcomes for patients with mHSPC. The study will help determine if this new combination treatment can help control the cancer more effectively than the standard care alone. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.